A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2016
At a glance
- Drugs ASP 3026 (Primary)
- Indications B cell lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 27 Jun 2016 Status changed from active, no longer recruiting to completed.
- 09 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
- 29 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.